Login Register Cart 0
Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact

Author(s): Debayan Sil, Shreastha Gautam, Shubhi Saxena, Sachin Joshi, Dinesh Kumar, Astha Mehta, Priya Jindal, Subhi Sharma, Prachi Pandey, Diksha and Amandeep Singh*

Volume 25, Issue 8, 2024

Published on: 09 May, 2024

Page: [517 - 525] Pages: 9

DOI: 10.2174/0113894501296586240430061915

Price: $65

Abstract

The emergence of new variants of the SARS-CoV-2 virus during the COVID-19 pandemic has prompted significant developments in the understanding, monitoring, and response to these strains. This comprehensive review focuses on two prominent variants of interest (VoI), XBB. 1.5 (Kraken) and XBB.1.16 (“Arcturus”), along with seven variants under observation (VuM), including EG.5. The World Health Organization (WHO) identified these variants in July 2023, highlighting EG.5's noteworthy rise in prevalence. EG.5, also known as “Eris,” has exhibited an increased effective reproductive rate, prompting concerns about its contagiousness and immune evasion capabilities. With an altered spike protein in the Receptor-Binding Domain (RBD), EG.5 shares similarities with XBB.1.5 but surpasses it in prevalence, constituting 20% of COVID-19 cases in the United States by late August. EG.5's subvariant, EG.5.1, poses challenges with mutations like Q52H and F456L, contributing to its ability to bypass neutralizing antibodies. The global distribution of SARS-CoV-2 variants presents a dynamic landscape, with XBB.1.16 and other strains gaining prominence. The advent of the BA.2.86 variant further complicates the scenario, with its notable spread in regions lacking robust viral surveillance. A thorough analysis of mutations reveals the evolving nature of the Omicron variant, with distinct amino acid changes characterizing XBB.1.5, XBB.1.16, and EG.5. The WHO designates EG.5 as a “variant of interest” due to its increased contagiousness and potential immune evasion, emphasizing the need for vigilant monitoring. The risk assessment of EG.5 underscores its rapid development and growing prevalence globally. While booster vaccines targeting XBB.1.5 are in development, antiviral medications like nirmatrelvir/ritonavir (Paxlovid) continue to exhibit efficacy. In the context of the evolving variants, the FDA has granted emergency use authorization for updated COVID-19 vaccines targeting circulating strains, reflecting the adaptability of vaccination strategies to address emerging challenges. This comprehensive overview provides a nuanced understanding of the diverse Omicron subvariants, their global impact, and the ongoing efforts to combat their spread through vaccination and therapeutic interventions.

« Previous Next »
Graphical Abstract

[1]
Dyer O. Covid-19: Infections climb globally as EG. 5 variant gains ground. BMJ 2023; 382: 1900.
[2]
Everything we know about EG. 5, the Covid subvariant dominating the US. Available from: https://www.independent.co.uk/news/world/americas/covid-variant-eris-symptoms-b2414981.html
[3]
Kaku Y, Kosugi Y, Uriu K, et al. Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5. Lancet Infect Dis 2023; 23(10): e395-6.
[http://dx.doi.org/10.1016/S1473-3099(23)00553-4] [PMID: 37708910]
[4]
An Y. Neutralization of SARS-CoV-2 EG. 5/EG. 5.1 by sera from ZF2001 RBD-dimer and its next-generation vaccines. bioRxiv 2023; 2023.09.
[http://dx.doi.org/10.1101/2023.09.02.556038]
[5]
Scarpa F, Pascarella S, Ciccozzi A, et al. Genetic and structural analyses reveal the low potential of the SARS-CoV-2 EG.5 variant. J Med Virol 2023; 95(9): e29075.
[http://dx.doi.org/10.1002/jmv.29075] [PMID: 37665162]
[6]
Wang Q. Antibody neutralization of emerging SARS-CoV-2: EG. 5.1 and XBC. 1.6. bioRxiv 2023; 2023.08.
[http://dx.doi.org/10.1101/2023.08.21.553968]
[7]
Uraki R. Characterization of an EG. 5.1 clinical isolate in vitro and in vivo. bioRxiv 2023; 2023.08.
[8]
Looi M-K. Covid-19: Scientists sound alarm over new BA 286 “Pirola” variant. British Medical Journal Publishing Group 2023.
[9]
Fact sheet: Omicron variant. Available from: https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Omicron-Variant-Fact-Sheet.aspx (Accessed on: 02/12/2023).
[10]
Mahase E. Covid-19: What do we know about XBB. 1.5 and should we be worried? BMJ 2023; 380: 153.
[11]
Abbasi J. What to know about EG.5, the latest SARS-CoV-2 “Variant of Interest”. JAMA 2023; 2024(10): 900-1.
[12]
SARS-CoV-2 variant classifications and definitions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html (Accessed on: 02/12/2023).
[13]
Ao D, He X, Hong W, Wei X. The rapid rise of SARS-CoV-2 omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants. MedComm 2023; 4(2): e239.
[http://dx.doi.org/10.1002/mco2.239] [PMID: 36938325]
[14]
Parums DV. Editorial: The XBB.1.5 (‘Kraken’) subvariant of omicron SARS-CoV-2 and its rapid global spread. Med Sci Monit 2023; 29: e939580-1.
[http://dx.doi.org/10.12659/MSM.939580] [PMID: 36722047]
[15]
Tracking SARS-CoV-2 variants. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants
[16]
Yue C. Enhanced transmissibility of XBB. 1.5 is contributed by both strong ACE2 binding and antibody evasion. bioRxiv 2023; 2023.01.
[http://dx.doi.org/10.1101/2023.01.03.522427]
[17]
Yamasoba D, Uriu K, Plianchaisuk A, et al. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect Dis 2023; 23(6): 655-6.
[http://dx.doi.org/10.1016/S1473-3099(23)00278-5] [PMID: 37148902]
[18]
Wang Q, Guo Y, Zhang RM, et al. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect Dis 2023; 23(10): e397-8.
[http://dx.doi.org/10.1016/S1473-3099(23)00555-8] [PMID: 37708906]
[19]
Hoffmann M, Arora P, Nehlmeier I, et al. Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5. Cell Mol Immunol 2023; 20(4): 419-22.
[http://dx.doi.org/10.1038/s41423-023-00988-0] [PMID: 36869193]
[20]
Graham F. Daily briefing: Is subvariant XBB.1.5 a global threat? Nature 2023; 2023: Online ahead of print.
[http://dx.doi.org/10.1038/d41586-023-00052-x] [PMID: 36631585]
[21]
XBB.1.5 omicron subvariant: Questions patients may have. Available from: https://www.ama-assn.org/delivering-care/public-health/xbb15-omicron-subvariant-questions-patients-may-have (Accessed on: 02/12/2023).
[22]
SARS-CoV-2 variants of concern and variants under investigation in England. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1129169/variant-technical-briefing-49-11-january-2023.pdf (Accessed on: 02/12/2023).
[23]
John OO, Olabode ON, Lucero-Prisno DE III, Adebimpe OT, Singh A. XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness. J Taibah Univ Med Sci 2023; 18(6): 1285-7.
[http://dx.doi.org/10.1016/j.jtumed.2023.05.013] [PMID: 37250814]
[24]
XBB.1.16 updated risk assessment, 05 June 2023. Available from: https://www.who.int/docs/default-source/coronaviruse/05062023xbb.1.16.pdf?sfvrsn=f1845468_3 (Accessed on: 02/12/2023)
[25]
EG.5 updated risk evaluation, 21 September 2023. Available from: https://www.who.int/docs/default-source/coronaviruse/eg5-risk-evaluation.pdf?sfvrsn=6e9690e0_4 (Accessed on: 02/12/2023).
[26]
EG.5 initial risk evaluation, 9 August 2023. Available from: https://www.who.int/docs/default-source/coronaviruse/09082023eg.5_ire_final.pdf (Accessed on: 02/12/2023).
[27]
SARS-CoV-2 genome sequence prevalence and growth rate update: 2 August 2023. Available from: https://www.gov.uk/government/publications/sars-cov-2-genome-sequence-prevalence-and-growth-rate/sars-cov-2-genome-sequence-prevalence-and-growth-rate-update-2-august-2023 (Accessed on: 02/12/2023).
[28]
COVID variant EG.5: What we know about eris. Available from: https://www.hindustantimes.com/lifestyle/health/covid-variant-eg-5-what-we-know-about-eris-101692259810058.html (Accessed on 02/12/2023).
[29]
What to know about EG.5 (Eris)—the latest coronavirus strain. Available from: https://www.yalemedicine.org/news/covid-eg5-eris-latest-coronavirus-strain (Accessed on: 02/12/2023).
[30]
Covid hospitalizations spike with new variant as school returns, U.S. readies vaccines. Available from: https://www.cnbc.com/2023/09/06/covid-hospitalizations-spike-with-new-variant-as-us-readies-vaccines.html (Accessed on: 02/12/2023).
[31]
COVID-19 variant ‘eris’ still dominates, but hospitalizations are slowing. Available from: https://www.everydayhealth.com/coronavirus/new-covid-19-variant-eg5-may-be-driving-uptick-in-infections/ (Accessed on: 02/12/2023).
[32]
COVID-19 vaccines for 2023-2024. Available from: www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines-2023-2024 (Accessed on: 02/12/2023).
[33]
Moderna, Pfizer say updated COVID-19 vaccines protect against EG.5. Available from: https://www.healio.com/news/infectious-disease/20230818/moderna-pfizer-say-updated-covid19-vaccines-protect-against-eg5 (Accessed on: 02/12/2023).
[34]
Available from: www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted (Accessed on: 02/12/2023).
[35]
Pfizer-BioNTech COVID-19 vaccine COMIRNATY® receives full U.S. FDA approval for individuals 16 years and older. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-comirnatyr-receives-full/ (Accessed on: 02/12/2023).
[36]
Information for recipients and caregivers. Available from: https://www.fda.gov/media/155762/download (Accessed on: 02/12/2023).

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy